Title:
ANTI-TIGIT HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/046097
Kind Code:
A1
Abstract:
Provided are an anti-TIGIT humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody or the antigen-binding fragment thereof has good binding activity and blocking activity, has a significant anti-tumor effect, effectively prolongs the survival period of mice, significantly reduces the proportion of Treg cells in healthy human PBMC and tumor infiltrating lymphocytes, is good in stability and good in druggability, and can be widely used for preventing or treating immune diseases or tumor-related diseases.
Inventors:
LU DI (CN)
HU PEIPEI (CN)
OU YINGYE (CN)
HUO YONGTING (CN)
LIU YUNPENG (CN)
LUO TIAN (CN)
LU LISHENG (CN)
HU PEIPEI (CN)
OU YINGYE (CN)
HUO YONGTING (CN)
LIU YUNPENG (CN)
LUO TIAN (CN)
LU LISHENG (CN)
Application Number:
PCT/CN2022/120984
Publication Date:
March 30, 2023
Filing Date:
September 23, 2022
Export Citation:
Assignee:
GUANGDONG FEIPENG PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C12N15/13
Domestic Patent References:
| WO2020098734A1 | 2020-05-22 | |||
| WO2019168382A1 | 2019-09-06 | |||
| WO2021092196A1 | 2021-05-14 |
Foreign References:
| CN112794909A | 2021-05-14 | |||
| CN109384846A | 2019-02-26 | |||
| CN110352200A | 2019-10-18 | |||
| CN111744007A | 2020-10-09 |
Other References:
DIXON, K. O. ET AL.: "Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.", THE JOURNAL OF IMMUNOLOGY, vol. 200, 2 March 2018 (2018-03-02), pages 3000 - 3007, XP055929655, DOI: 10.4049/jimmunol.1700407
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF: